FY2024 EPS Estimates for CRVS Cut by Cantor Fitzgerald

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Analysts at Cantor Fitzgerald cut their FY2024 earnings estimates for shares of Corvus Pharmaceuticals in a research report issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($0.91) for the year, down from their prior estimate of ($0.50). The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.68) per share.

Several other research firms have also recently issued reports on CRVS. LADENBURG THALM/SH SH raised their target price on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a "buy" rating in a research note on Monday, September 16th. Mizuho upgraded shares of Corvus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, October 22nd. StockNews.com cut shares of Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, October 31st. Finally, Oppenheimer upped their target price on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Corvus Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.83.

Corvus Pharmaceuticals Stock Up 1.8 %

CRVS traded up $0.15 during trading on Monday, reaching $8.34. The company's stock had a trading volume of 636,972 shares, compared to its average volume of 372,278. The firm has a fifty day simple moving average of $6.83 and a two-hundred day simple moving average of $4.08. The company has a market cap of $535.90 million, a price-to-earnings ratio of -9.32 and a beta of 1.05. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00.

Hedge Funds Weigh In On Corvus Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. bought a new stake in Corvus Pharmaceuticals in the second quarter valued at about $10,855,000. Samlyn Capital LLC raised its stake in Corvus Pharmaceuticals by 160.7% during the 2nd quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company's stock valued at $11,144,000 after acquiring an additional 3,774,658 shares in the last quarter. Vanguard Group Inc. increased its stake in Corvus Pharmaceuticals by 10.6% during the 1st quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company's stock valued at $2,658,000 after buying an additional 142,724 shares during the period. Geode Capital Management LLC lifted its position in Corvus Pharmaceuticals by 22.4% in the third quarter. Geode Capital Management LLC now owns 563,009 shares of the company's stock worth $2,974,000 after purchasing an additional 102,869 shares during the period. Finally, Marshall Wace LLP bought a new position in Corvus Pharmaceuticals during the second quarter valued at about $136,000. Hedge funds and other institutional investors own 46.64% of the company's stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.